Clinical Trial: CoQ10 and D-ribose in Patients With Diastolic Heart Failure

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose

Brief Summary: The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).

Detailed Summary:
Sponsor: University of Kansas Medical Center

Current Primary Outcome: Change in health status of patients with HFpEF [ Time Frame: Change from Baseline to Week 12 ]

Patients' perceptions of their symptoms will be measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a self-administered questionnaire that measures patients' perceptions of five domains of their health status relevant to HFpEF. The KCCQ is a 24 item questionnaire. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Change in vigor [ Time Frame: Change from Baseline to Week 12 ]
    Change will be measured using the the Vigor subscale from the Profile of Mood States (POMS) questionnaire.The subscale has 8 questions. Scores for the subscale range from 0-32, in which higher scores reflect more vigor.
  • Left ventricular diastolic function [ Time Frame: Change from Baseline to Week 12 ]
    Change will be measured using advanced echocardiographic imaging.
  • Change in 6 minute walk test (6MWT) [ Time Frame: Change from Baseline to Week 12 ]
    The 6-minute walking test (6MWT) is a simple test. Test measures the total distance in meters a person can walk in 6 minutes.
  • Change in venous blood B-type natriuretic peptide (BNP) levels [ Time Frame: Change from Baseline to Week 12 ]
    BNP concentration will be measured.
  • Change in lactate/adenosine triphosphate (ATP) ratio [ Time Frame: Change from Baseline to Week 12 ]
    The lactate/ATP ratio will be measured for each participant.


Original Secondary Outcome: Same as current

Information By: University of Kansas Medical Center

Dates:
Date Received: April 25, 2017
Date Started: November 2017
Date Completion: March 2020
Last Updated: April 25, 2017
Last Verified: April 2017